Search PubMed:   

Publikationen 2008

Editorials

  1. Altschmied J, Haendeler J (2008) A new kid on the block: PKD1: a promising target for antiangiogenic therapy? ARTERIOSCL THROM VAS, 28(10): 1689-90
    Letter
  2. Burmeister T, Schwartz S, Bartram CR, Gökbuget N, Hoelzer D, Thiel E, GMALL study group (2008) Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. BLOOD, 112(3): 918-9
  3. Schindewolf M, Ludwig RJ, Wolter M, Himsel A, Zgouras D, Kaufmann R, Boehncke WH, Lindhoff-Last E (2008) Tolerance of fondaparinux in patients with generalized contact dermatitis to heparin. J Eur Acad Dermatol Venereol, 22(3): 378-80

Originalarbeiten

  1. Agrawal S, Koschmieder S, Bäumer N, Reddy NG, Berdel WE, Müller-Tidow C, Serve H (2008) Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation. LEUKEMIA, 22(1): 78-86
  2. Antiretroviral Therapy Cohort Collaboration. (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. LANCET, 372(9635): 293-9
  3. Antiretroviral-Therapy-Cohort-Collaboration-(ART-CC), Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Günthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F, Miró JM, Staszewski S, Sterne JA (2008) Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS, 22(18): 2481-92
  4. Autran B, Murphy RL, Costagliola D, Tubiana R, Clotet B, Gatell J, Staszewski S, Wincker N, Assoumou L, El-Habib R, Calvez V, Walker B, Katlama C, ORVACS Study Group (2008) Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS, 22(11): 1313-22
  5. Baak U, Gökbuget N, Orawa H, Schwartz S, Hoelzer D, Thiel E, Burmeister T, German Multicenter ALL Study Group (2008) Thymic adult T-cell acute lymphoblastic leukemia stratified in standard- and high-risk group by aberrant HOX11L2 expression: experience of the German multicenter ALL study group. LEUKEMIA, 22(6): 1154-60
  6. Bangsow T, Baumann E, Bangsow C, Jaeger MH, Pelzer B, Gruhn P, Wolf S, von Melchner H, Stanimirovic DB (2008) The epithelial membrane protein 1 is a novel tight junction protein of the blood-brain barrier. J CEREBR BLOOD F MET, 28(6): 1249-60
  7. Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte A, Clotet B, Lundgren JD, EuroSIDA study group (2008) Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS, 22(3): 367-76
  8. Baeumler J, Szuhai K, Falkenburg JH, van Schie ML, Ottmann OG, Nijmeijer BA (2008) Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement. Cancer Genet Cytogenet, 185(1): 37-42
  9. Beck O, Koehl U, Tramsen L, Mousset S, Latgé JP, Müller K, Schwabe D, Bader P, Klingebiel T, Lehrnbecher T (2008) Enumeration of functionally active anti-Aspergillus T-cells in human peripheral blood. J IMMUNOL METHODS, 335(1-2): 41-5
  10. Beissert T, Hundertmark A, Kaburova V, Travaglini L, Mian AA, Nervi C, Ruthardt M (2008) Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. INT J CANCER, 122(12): 2744-52
  11. Bergmann L, Aamdal S, Marreaud S, Lacombe D, Herold M, Yamaguchi T, Wilhelm-Ogunbiyi K, Lentzen H, Zwierzina H, European Organisation for Research and Treatment of Cancer (2008) Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001). EUR J CANCER, 44(12): 1657-62
  12. Bickel M, Zangos S, Lutz T, Eisen J, Knecht G, Goebel FD, Crespi CM, Jacobi V, Staszewski S, Klauke S (2008) Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy. SCAND J INFECT DIS, 40(1): 36-9
  13. Binninger-Schinzel D, Müller D, Wolf T, Krause B, Meye B, Winskowsky G, Raupp S, Norley S, Brodt R, Werner A (2008) Characterization of a chemokine receptor CCR5-negative T cell line and its use in determining human immunodeficiency virus type 1 phenotype. J MED VIROL, 80(2): 192-200
  14. Böiers U, Lanig H, Sehnert B, Holmdahl R, Burkhardt H (2008) Collagen type II is recognized by a pathogenic antibody through germline encoded structures. EUR J IMMUNOL, 38(10): 2784-95
  15. Brixner V, Richter R, Bader P, Seifried E, Seidl C (2008) A new HLA-B*08 allele, HLA-B*0828, found in two voluntary stem cell donors. TISSUE ANTIGENS, 71(5): 482-3
  16. Brück P, Ramos-Lopez E, Bartsch W, Böhme A, Badenhoop K (2008) TIM-3 polymorphisms in type 1 diabetes families. J HUM GENET, 53(6): 559-64
  17. Bulk E, Hascher A, Liersch R, Mesters RM, Diederichs S, Sargin B, Gerke V, Hotfilder M, Vormoor J, Berdel WE, Serve H, Müller-Tidow C (2008) Adjuvant therapy with small hairpin RNA interference prevents non-small cell lung cancer metastasis development in mice. CANCER RES, 68(6): 1896-904
  18. Cornely OA, Böhme A, Reichert D, Reuter S, Maschmeyer G, Maertens J, Buchheidt D, Paluszewska M, Arenz D, Bethe U, Effelsberg J, Lövenich H, Sieniawski M, Haas A, Einsele H, Eimermacher H, Martino R, Silling G, Hahn M, Wacker S, Ullmann AJ, Karthaus M, Multinational Case Registry of the Infectious Diseases Working Party of the German Society for Hematology and Oncology (2008) Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J ANTIMICROB CHEMOTH, 61(4): 939-46
  19. Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Furst DE, EPOSS-Omeract-Group (2008) Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. ARTH RHEUM/AR C RES, 59(6): 867-75
  20. Ernst T, Erben P, Müller MC, Paschka P, Schenk T, Hoffmann J, Kreil S, La Rosée P, Hehlmann R, Hochhaus A (2008) Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. HAEMATOL-HEMATOL J, 93(2): 186-92
  21. Floss T, Schnütgen F (2008) Conditional gene trapping using the FLEx system. Methods Mol Biol, 435: 127-38
  22. Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J, SMART Study Group (2008) Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS, 22(17): 2279-89
  23. Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S (2008) Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. ANTIVIR THER, 13(7): 927-36
  24. Gladman DD, Rahman P, Krueger GG, Mease PJ, Qureshi AA, Dutz JP, Lindqvist U, Carneiro S, Helliwell PS, Ujfalussy I, Gottlieb AB, Behrens F, Ståhle M (2008) Clinical and genetic registries in psoriatic disease. J RHEUMATOL, 35(7): 1458-63
  25. Graff J, von Hentig N, Kuczka K, Angioni C, Gute P, Klauke S, Babacan E, Harder S (2008) Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo. J ANTIMICROB CHEMOTH, 61(2): 394-399
  26. Guardiola-Serrano F, Haendeler J, Lukosz M, Sturm K, Melchner H, Altschmied J (2008) Gene trapping identifies a putative tumor suppressor and a new inducer of cell migration. BIOCHEM BIOPH RES CO, 376(4): 748-52
  27. Gueller S, Gery S, Nowak V, Liu L, Serve H, Koeffler HP (2008) Adaptor protein Lnk associates with Tyr(568) in c-Kit. BIOCHEM J, 415(2): 241-5
  28. Haritunians T, Gueller S, O'Kelly J, Ilaria R, Koeffler HP (2008) Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells. ONCOL REP, 20(5): 1237-42
  29. Haritunians T, Gueller S, Zhang L, Badr R, Yin D, Xing H, Fung MC, Koeffler HP (2008) Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells. LEUKEMIA RES, 32(9): 1366-73
  30. Hoemme C, Peerzada A, Behre G, Wang Y, McClelland M, Nieselt K, Zschunke M, Disselhoff C, Agrawal S, Isken F, Tidow N, Berdel WE, Serve H, Muller-Tidow C (2008) Chromatin modifications induced by PML-RAR{alpha} repress critical targets in leukemogenesis as analyzed by ChIP-Chip. BLOOD, 111(5): 2887-95
  31. Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ (2008) Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. TRANSFUSION, 48(8): 1558-66
  32. Hüffmeier U, Böiers U, Lascorz J, Reis A, Burkhardt H (2008) Loss-of-function mutations in the filaggrin gene: no contribution to disease susceptibility, but to autoantibody formation against citrullinated peptides in early rheumatoid arthritis. ANN RHEUM DIS, 67(1): 131-3
  33. Isken F, Steffen B, Merk S, Dugas M, Markus B, Tidow N, Zühlsdorf M, Illmer T, Thiede C, Berdel WE, Serve H, Müller-Tidow C (2008) Identification of acute myeloid leukaemia associated microRNA expression patterns. BRIT J HAEMATOL, 140(2): 153-61
  34. Jakob S, Schroeder P, Lukosz M, Büchner N, Spyridopoulos I, Altschmied J, Haendeler J (2008) Nuclear protein tyrosine phosphatase Shp-2 is one important negative regulator of nuclear export of telomerase reverse transcriptase. J BIOL CHEM, 283(48): 33155-61
  35. Jelinek T, Schade Larsen C, Siikamaki H, Myrvang B, Chiodini P, Gascon J, Visser L, Kapaun A, Just-Nubling G (2008) European cluster of imported falciparum malaria from Gambia. Euro Surveill, 13(51): 19077
  36. Jilani I, Kantarjian H, Faraji H, Gorre M, Cortes J, Ottmann O, Bhalla K, O'Brien S, Giles F, Albitar M (2008) An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. LEUKEMIA RES, 32(6): 936-43
  37. Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, Giles FJ, Albitar M (2008) Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. LEUKEMIA RES, 32(4): 643-9
  38. Kessler T, Mohr M, Müller-Tidow C, Krug U, Brunnberg U, Mohr B, Schliemann C, Sauerland C, Serve H, Büchner T, Berdel WE, Mesters RM (2008) Amsacrine containing induction therapy in elderly AML patients: Comparison to standard induction regimens in a matched-pair analysis. LEUKEMIA RES, 32(3): 491-4
  39. Khaykin P, Postel N, Reeb I, Staszewski S (2008) Switch to efavirenz (EFV) after protease-inhibitor (PI)-failure: explorative analysis of outcome by baseline viral VS tolerability failure. EUR J MED RES, 13(4): 169-72
  40. Klarmann D; Martinez Saguer I; Funk MB; Knoefler R; von Hentig N; Heller C; Kreuz W (2008) Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor. HAEMOPHILIA, 14(1): 44-9
  41. Kucheryava N, Bowen JK, Sutherland PW, Conolly JJ, Mesarich CH, Rikkerink EH, Kemen E, Plummer KM, Hahn M, Templeton MD (2008) Two novel Venturia inaequalis genes induced upon morphogenetic differentiation during infection and in vitro growth on cellophane. FUNGAL GENET BIOL, 45(10): 1329-39
  42. Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD, Cancer and Leukemia Group B (CALGB) (2008) High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. BLOOD, 111(11): 5371-9
  43. La Rosée P, Holm-Eriksen S, Konig H, Härtel N, Ernst T, Debatin J, Mueller MC, Erben P, Binckebanck A, Wunderle L, Shou Y, Dugan M, Hehlmann R, Ottmann OG, Hochhaus A (2008) Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib. HAEMATOL-HEMATOL J, 93(5): 765-9
  44. le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Kwong YI, Baccarani M, Hughes T, Martinelli G, Radich JP, Zheng M, Shou Y, Kantarjian H (2008) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated phase chronic myelogenous leukemia. BLOOD, 111(4): 1834-9
  45. Liebner S, Corada M, Bangsow T, Babbage J, Taddei A, Czupalla CJ, Reis M, Felici A, Wolburg H, Fruttiger M, Taketo MM, von Melchner H, Plate KH, Gerhardt H, Dejana E (2008) Wnt/beta-catenin signaling controls development of the blood-brain barrier. J CELL BIOL, 183(3): 409-17
  46. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GM, Croockewit S, Zweegman S, Breitkreuz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MH, Schaafsma R, Naumann R, Sinnige H, Blau I, Verhoef G, de Weerdt O, Wijermans P, Wittebol S, Duersen U, Vellenga E, Goldschmidt H, Dutch-Belgian-HOVON, German GMMG (2008) Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. HAEMATOL-HEMATOL J, 93(1): 124-7
  47. Lorenz MW, Stephan C, Harmjanz A, Staszewski S, Buehler A, Bickel M, von Kegler S, Ruhkamp D, Steinmetz H, Sitzer M (2008) Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. ATHEROSCLEROSIS, 196(2): 720-6
  48. Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Häntzschel H, Baerwald CG (2008) Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. J RHEUMATOL, 35(6): 979-85
  49. Malysheva O, Pierer M, Wagner U, Wahle M, Wagner U, Baerwald CG (2008) Association between beta2 adrenergic receptor polymorphisms and rheumatoid arthritis in conjunction with human leukocyte antigen (HLA)-DRB1 shared epitope. ANN RHEUM DIS, 67(12): 1759-64
  50. Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD (2008) Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J CLIN ONCOL, 26(31): 5078-87
  51. Marcucci G, Radmacher MD, Maharry K, Mrózek K, Ruppert AS, Paschka P, Vukosavljevic T, Whitman SP, Baldus CD, Langer C, Liu CG, Carroll AJ, Powell BL, Garzon R, Croce CM, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD (2008) MicroRNA expression in cytogenetically normal acute myeloid leukemia. NEW ENGL J MED, 358(18): 1919-28
  52. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC, Heinecke A, Radmacher M, Marcucci G, Whitman SP, Maharry K, Paschka P, Larson RA, Berdel WE, Büchner T, Wörmann B, Mansmann U, Hiddemann W, Bohlander SK, Buske C, Cancer and Leukemia Group B, German AML Cooperative Group (2008) An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. BLOOD, 112(10): 4193-201
  53. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bra